BAFL 45.05 Increased By ▲ 0.25 (0.56%)
BIPL 20.51 Decreased By ▼ -0.47 (-2.24%)
BOP 5.64 Increased By ▲ 0.36 (6.82%)
CNERGY 4.55 Increased By ▲ 0.13 (2.94%)
DFML 15.70 Decreased By ▼ -0.11 (-0.7%)
DGKC 71.21 Decreased By ▼ -0.10 (-0.14%)
FABL 27.40 Decreased By ▼ -0.40 (-1.44%)
FCCL 17.15 Decreased By ▼ -0.14 (-0.81%)
FFL 8.55 Decreased By ▼ -0.19 (-2.17%)
GGL 12.67 Decreased By ▼ -0.49 (-3.72%)
HBL 112.70 Decreased By ▼ -0.70 (-0.62%)
HUBC 119.11 Decreased By ▼ -2.79 (-2.29%)
HUMNL 7.60 Decreased By ▼ -0.34 (-4.28%)
KEL 3.27 Decreased By ▼ -0.10 (-2.97%)
LOTCHEM 27.85 Decreased By ▼ -0.05 (-0.18%)
MLCF 39.08 Decreased By ▼ -0.35 (-0.89%)
OGDC 108.31 Decreased By ▼ -0.96 (-0.88%)
PAEL 17.75 Decreased By ▼ -0.55 (-3.01%)
PIBTL 5.56 Decreased By ▼ -0.18 (-3.14%)
PIOC 106.00 Decreased By ▼ -4.00 (-3.64%)
PPL 92.50 Decreased By ▼ -1.11 (-1.19%)
PRL 25.34 Increased By ▲ 0.19 (0.76%)
SILK 1.07 Increased By ▲ 0.01 (0.94%)
SNGP 63.72 Increased By ▲ 0.02 (0.03%)
SSGC 12.00 Decreased By ▼ -0.25 (-2.04%)
TELE 8.46 Decreased By ▼ -0.42 (-4.73%)
TPLP 13.34 Decreased By ▼ -0.56 (-4.03%)
TRG 85.40 Decreased By ▼ -0.40 (-0.47%)
UNITY 25.96 Decreased By ▼ -0.14 (-0.54%)
WTL 1.54 Decreased By ▼ -0.06 (-3.75%)
BR100 6,185 Decreased By -45.4 (-0.73%)
BR30 21,452 Decreased By -287.1 (-1.32%)
KSE100 60,502 Decreased By -228.3 (-0.38%)
KSE30 20,175 Decreased By -64.2 (-0.32%)

Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.

The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against Omicron in human studies, the companies said.

Molnupiravir and a rival oral pill from Pfizer Inc were authorized in the United States in December and are considered as important tools against Omicron.

Merck expects COVID-19 pill molnupiravir to be effective against Omicron

Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against Omicron.

Merck said earlier this month its pill has a mechanism that can work against Omicron and any other variant.

Molnupiravir has been authorized for use in more than 10 countries, including the United States, United Kingdom and Japan.

Comments

Comments are closed.

Merck's COVID-19 pill active against Omicron in lab studies

IHC acquits Nawaz Sharif in Avenfield reference

Imran Khan will not take part in intra-party polls, PTI announces

Inter-bank: rupee registers back-to-back gains against US dollar

Open-market: rupee unchanged against US dollar

Caretaker PM meets Kuwait’s First Deputy Prime Minister

Israel, Hamas due to release more people amid efforts to extend truce

TPL Life Insurance, Dar Es Salam Textile Mills move ahead with merger talks

Oil gains ahead of OPEC+ meeting as Black Sea shutdowns support

Gold price per tola jumps Rs2,600 in Pakistan

Pakistan players told to put country before franchise leagues